Subject: BICX Volume Explodes on Strong Financial Results Up 10%

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BICX Volume Explodes on Strong Financial Results Up 10%
Hot Stock to WatchHot Stock to Watch

Company: BioCorRx Inc. (OTCQB: BICX)


Price: 0.1249

Change (%): + 0.0249 (24.90)

Volume: 156,262

BioCorRx, Inc. Reports 2014 Financial Results

Los Angeles, April 2, 2015 (GLOBE NEWSWIRE) - BioCorRx, Inc. (BICX), developer of the Start Fresh Program® used for the treatment of alcohol and opioid dependence, announces its 2014 Financial Results with highlights as follows:

Increased revenues by 64% over 2013 led by our Start Fresh Program fees.

Over a 400% increase in patients treated with the Start Fresh Program from 2013 to 2014.

Successfully closed out 6 licensing agreements and strategic partnerships granting licensing rights to the Start Fresh Program in territories throughout the United States.

Eliminated nearly 1 million dollars in convertible debt, improving the capital structure of BioCorRx and strengthening the Company’s balance sheet.

2014 GAAP Financial Summary:
  • Revenues were 1.17 million dollars.
  • Net cash from continuing operations was $167,700.
  • Net Loss was 3.1 million dollars.
Non-GAAP Adjusted EBITDA:
  • Adjusted EBITDA was a loss of 1.1 million dollars.
“Our record year ended with a total of 10 clinics offering the Start Fresh program by year end. It was a great end to what was an all-around successful year for BioCorRx Inc.” said Lourdes Felix, CFO of BioCorRx Inc. “We were able to upsurge our Start Fresh Program while continuing to execute and further expand our core market. Moving on to 2015, we will continue to look for and create opportunities for growth and expansion through strategic relationships like the ones we have created with EROI and Myriad Medical Marketing. We also look forward to the potential acquisition of Trinity Compound Solutions this year and their list of formulas, including the formula for the Naltrexone implant which we already have exclusive rights to (except Australia and New Zealand) and is used in the Start Fresh Program. Our vision remains to provide benefit to our shareholders, strategic partners, employees and more importantly, the families that are helped by our wonderful program.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks